Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.02
▼(-36.67% Downside)
Action:ReiteratedDate:03/01/26
The score is primarily weighed down by weak financial performance (zero revenue in 2025, persistent losses, negative cash flow, and negative equity indicating higher solvency and funding risk). Technical indicators are broadly neutral with slightly negative momentum, while valuation metrics offer limited support due to a negative P/E and no dividend yield data.
Positive Factors
Oncology-focused imaging tech
Imagion’s core focus on molecular imaging agents for oncology that work with standard clinical imaging systems is a durable strategic advantage. Targeting cancer detection aligns with structural healthcare demand and supports long-term partner, clinical and reimbursement pathways independent of short-term market moves.
Negative Factors
Zero revenue in 2025
Reporting zero revenue in 2025 is a major structural weakness: it indicates the company has not monetized its technology at scale. Sustained lack of revenue forces reliance on external funding, prevents internal reinvestment, and makes commercialization and scalable profitability uncertain over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Oncology-focused imaging tech
Imagion’s core focus on molecular imaging agents for oncology that work with standard clinical imaging systems is a durable strategic advantage. Targeting cancer detection aligns with structural healthcare demand and supports long-term partner, clinical and reimbursement pathways independent of short-term market moves.
Read all positive factors
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$11.28M
Dividend YieldN/A
Average Volume (3M)16.05M
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue Growth-47.02%
EPS Growth94.37%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superpara...
How the Company Makes Money
null...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | |||||
| Total Assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | |||||
| Free Cash Flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Technical Analysis
Negative
0.03
Price Trends
0.02
Negative
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
46.02
Neutral
35.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 35.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IBX.
Imagion Biosystems Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$53.20M | 10.72 | 72.82% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$168.57M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
43 Neutral | AU$11.28M | -1.61 | 142.99% | ― | -47.02% | 94.37% | |
42 Neutral | AU$33.18M | -2.45 | -164.22% | ― | ― | 23.85% | |
38 Underperform | AU$49.98M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:IBX
Imagion Biosystems Ltd.
0.02
0.01
76.92%
AU:BDX
BCAL Diagnostics Limited
0.09
-0.01
-10.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.21
0.19
950.00%
AU:CTE
Cryosite Limited
1.09
0.30
37.97%
AU:IIQ
Inoviq Ltd
0.36
-0.03
-6.58%
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Secures Extra Funding and Extends Note Maturities
Apr 8, 2026
Imagion Biosystems has secured an additional US$300,000 in short‑term funding from a fund managed by U.S.‑based C/M Capital Partners, under its existing convertible securities framework originally established with Mercer Street Global ...
Imagion Biosystems Sets 2026 AGM Date and Director Nomination Deadline
Apr 7, 2026
Imagion Biosystems has scheduled its 2026 Annual General Meeting for 26 May 2026 in Melbourne and has set 5pm AEST on 14 April 2026 as the deadline for shareholders to submit nominations for candidates to stand for election as directors. The forth...
Imagion Biosystems Reports Expiry of Unexercised Options
Apr 2, 2026
Imagion Biosystems Limited has notified the ASX of the cessation of a class of options, with 353,474 IBXAAR options expiring on March 23, 2026, without being exercised or converted. The expiry of these options slightly reduces the company’s ...
Imagion Biosystems addresses late ASX filing on convertible note repayment
Apr 2, 2026
Imagion Biosystems has advised that it recently lodged an Appendix 3H with the ASX relating to the part repayment of convertible notes held by Mercer Street Global Opportunity Fund, after the filing was submitted later than required due to an admi...
Imagion Biosystems Redeems 300,000 Convertible Notes Without Conversion
Apr 2, 2026
Imagion Biosystems has reported a change to its capital structure following the cessation of a tranche of its convertible securities. The company notified the ASX that 300,000 IBXAAQ convertible notes have been repaid or redeemed without conversio...
Imagion Biosystems posts wider 2025 loss with no revenue or dividends
Feb 27, 2026
Imagion Biosystems reported no revenue from ordinary activities for the year ended 31 December 2025, with its net loss after tax widening 108.5% to $4.31 million compared with the prior year. The company’s net tangible assets per share impro...
Imagion Biosystems Files IND with FDA for Phase 2 MagSense HER2 Breast Cancer Trial
Feb 1, 2026
Imagion Biosystems has submitted its first Investigational New Drug application to the U.S. Food and Drug Administration for its MagSense® HER2 imaging agent, a key step toward launching a Phase 2 clinical trial in HER2-positive breast cancer...
Imagion Advances MagSense HER2 Program Toward FDA IND and Bolsters US Leadership
Jan 29, 2026
Imagion Biosystems has completed manufacturing and independent analytical testing of its MagSense® HER2 Imaging Agent, clearing a key technical hurdle toward filing an Investigational New Drug application with the U.S. FDA in the first quarte...
Imagion Biosystems Issues New Shares on Mercer Note Conversion, Flags Imminent HER2+ Trial Filing
Jan 8, 2026
Imagion Biosystems has issued 3,048,484 new fully paid ordinary shares at a deemed price of 2.5 cents each following the conversion of 76,212 convertible notes held under its agreement with Mercer Street Global Opportunity Fund, LLC, leaving Merce...
Imagion Biosystems Seeks ASX Quotation for 3.0 Million New Shares
Jan 8, 2026
Imagion Biosystems Limited has applied to the ASX for quotation of 3,048,484 new fully paid ordinary shares, issued on 8 January 2026 following the exercise of options or conversion of other securities. The additional quotation expands the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.